SEC Form 4 · accession 0001209191-18-048223
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Aug 21, 2018
Accepted (ET)
Aug 23, 2018 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 21, 2018 | M | 43,000 | $0.47 | A | 1,573,562 | D | |
| Common Stock | Aug 21, 2018 | S | 43,000 | $3.75 | D | 1,530,562 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.47 | Aug 21, 2018 | M | 43,000 | D | — | Nov 11, 2018 | Common Stock | 43,000 | 0 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock options reported on this Form 4 were due to expire on November 11, 2018.
- F2The options vested and became exercisable in equal quarterly installments over three years following the grant date of November 12, 2008.